

Propensity score matching

Overall population (n=18108)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1660)

3–5 mmol/mol (n=2094)

0–3 mmol/mol (n=5630)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=5050)

3–5 mmol/mol (n=2296)

>5 mmol/mol (n=1378)

Average treatment effect



Propensity score matching + adjust

Overall population (n=18108)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1660)

3–5 mmol/mol (n=2094)

0–3 mmol/mol (n=5630)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=5050)

3–5 mmol/mol (n=2296)

>5 mmol/mol (n=1378)

Average treatment effect



Adjust

Overall population (n=47760)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=3616)

3–5 mmol/mol (n=4780)

0–3 mmol/mol (n=14660)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=15077)

3–5 mmol/mol (n=6191)

>5 mmol/mol (n=3436)


Average treatment effect



Propensity score matching

SGLT2 GLP1


Overall population (n=16280)



Propensity score matching + adjusted

SGLT2 GLP1


Overall population (n=16280)



Adjusted

SGLT2 GLP1

Overall population (n=41728)



eGFR change

Propensity score matching

SGLT2 GLP1

Overall population (n=16618)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1540)

3–5 mmol/mol (n=1936)

0–3 mmol/mol (n=5176)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=4720)

3–5 mmol/mol (n=1970)

>5 mmol/mol (n=1276)

Average treatment effect



Propensity score matching + adjusted

SGLT2 GLP1

Overall population (n=16618)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1540)

3–5 mmol/mol (n=1936)

0–3 mmol/mol (n=5176)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=4720)

3–5 mmol/mol (n=1970)

>5 mmol/mol (n=1276)

Average treatment effect



Adjusted

SGLT2 GLP1

Overall population (n=44339)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=3334)

3–5 mmol/mol (n=4405)

0–3 mmol/mol (n=13601)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=13990)

3–5 mmol/mol (n=5758)

>5 mmol/mol (n=3251)


Average treatment effect



Propensity score matching

SGLT2 GLP1


Overall population (n=30992)



Propensity score matching + adjusted

SGLT2 GLP1


Overall population (n=30992)



Adjusted

SGLT2 GLP1

Overall population (n=77741)



Propensity score matching

Overall population (n=17094)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1821, event = 38)

3–5 mmol/mol (n=2069, event = 37)

0–3 mmol/mol (n=5420, event = 147)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=4729, event = 139)

3–5 mmol/mol (n=2079, event = 58)

>5 mmol/mol (n=976, event = 47)

Average treatment effect



Propensity score matching + adjusted

Overall population (n=17094)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1821, event = 38)

3–5 mmol/mol (n=2069, event = 37)

0–3 mmol/mol (n=5420, event = 147)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=4729, event = 139)

3–5 mmol/mol (n=2079, event = 58)

>5 mmol/mol (n=976, event = 47)

Average treatment effect



Adjusted

Overall population (n=52052)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=4236, event = 80)

3–5 mmol/mol (n=5327, event = 97)

0–3 mmol/mol (n=16279, event = 382)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=16419, event = 412)

3–5 mmol/mol (n=6763, event = 160)

>5 mmol/mol (n=3028, event = 129)

Average treatment effect



Propensity score matching

Overall population (n=17094)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1821, event = 19)

3–5 mmol/mol (n=2069, event = 20)

0–3 mmol/mol (n=5420, event = 79)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=4729, event = 81)

3–5 mmol/mol (n=2079, event = 33)

>5 mmol/mol (n=976, event = 30)

Average treatment effect



Propensity score matching + adjusted

Overall population (n=17094)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1821, event = 19)

3–5 mmol/mol (n=2069, event = 20)

0–3 mmol/mol (n=5420, event = 79)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=4729, event = 81)

3–5 mmol/mol (n=2079, event = 33)

>5 mmol/mol (n=976, event = 30)

Average treatment effect



Adjusted

Overall population (n=52052)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=4236, event = 42)

3–5 mmol/mol (n=5327, event = 43)

0–3 mmol/mol (n=16279, event = 185)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=16419, event = 208)

3–5 mmol/mol (n=6763, event = 94)

>5 mmol/mol (n=3028, event = 83)

Average treatment effect



Propensity score matching

Overall population (n=18554)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1874, event = 21)

3–5 mmol/mol (n=2102, event = 13)

0–3 mmol/mol (n=5564, event = 61)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=5154, event = 68)

3–5 mmol/mol (n=2347, event = 24)

>5 mmol/mol (n=1513, event = 32)

Average treatment effect



Propensity score matching + adjusted

Overall population (n=18554)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1874, event = 21)

3–5 mmol/mol (n=2102, event = 13)

0–3 mmol/mol (n=5564, event = 61)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=5154, event = 68)

3–5 mmol/mol (n=2347, event = 24)

>5 mmol/mol (n=1513, event = 32)

Average treatment effect



Adjusted

Overall population (n=54852)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=4320, event = 43)

3–5 mmol/mol (n=5406, event = 41)

0–3 mmol/mol (n=16634, event = 173)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=17142, event = 198)

3–5 mmol/mol (n=7248, event = 79)

>5 mmol/mol (n=4102, event = 71)

Average treatment effect



Propensity score matching

Overall population (n=22842)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=2074, event = 7)

3–5 mmol/mol (n=2458, event = 10)

0–3 mmol/mol (n=6733, event = 37)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=6524, event = 37)

3–5 mmol/mol (n=3021, event = 22)

>5 mmol/mol (n=2032, event = 31)

Average treatment effect



Propensity score matching + adjusted

Overall population (n=22842)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=2074, event = 7)

3–5 mmol/mol (n=2458, event = 10)

0–3 mmol/mol (n=6733, event = 37)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=6524, event = 37)

3–5 mmol/mol (n=3021, event = 22)

>5 mmol/mol (n=2032, event = 31)

Average treatment effect



Adjusted

Overall population (n=66428)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=4765, event = 11)

3–5 mmol/mol (n=6188, event = 17)

0–3 mmol/mol (n=19413, event = 62)

Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=21327, event = 81)

3–5 mmol/mol (n=9219, event = 45)

>5 mmol/mol (n=5516, event = 63)

Average treatment effect

